Eae

marmoset model 309-10 ears, HHV-6 primary infection in children 174-6 EBV see Epstein-Barr virus enanthema, with Nagayama's papules 177f encephalitis 84, 98, 282t endothelial cells 64, 65, 142, 226, 234, 235f endothelial dysfunction 238-9 enterovirus 225 envelope 12, 15 envelope glycoproteins 52 envelope-mediated cell fusion assay 60 enzyme immunoassays 93-4 enzyme-linked immunosorbent assay (ELISA) 92,

93-4, 94, 95, 187 epidemiology 81, 119 animal model 307-8

incubation period 125-6 mode of transmission 123-5 of roseola 119-20 seroepidemiologic studies 120 viral acquisition 120-3 epilepsy 85

Epstein-Barr virus (EBV) 140, 190, 196, 249-50 with HIV-I 4-5 transactivation 201 exanthem subitum 139, 163, 164-5, 169, 174, 213, 214, 225

experimental allergic encephalomyelitis see EAE experimental coinfection models chimeric SCID-hu Thy/Liv mice 272 human lymphoid tissue 271-2 pig-tailed macaques 272-4 experimental therapeutic approaches ampligen 339-40 immunoglobulin 337-8 interferon 338-9 isoprinosine 341 transfer factor 340-1 eyes, primary infection in children 174-6

febrile seizures 214-15

exanthem subitum 214 febrile status epilepticus (FSE) 214 fibromyalgia 207, 209

fluorescence resonance energy transfer (FRET) 111

fluorescent in situ hybridization (FISH) 109, 197 foscarnet 258, 286, 287, 291, 293, 296 fulminant hepatic failure 143 fulminant hepatitis 244-5, 245t fungal infections 205, 285

gammaherpesvirus 12, 29, 30f ganciclovir 50, 258, 286, 287, 291, 291, 293, 295, 296

gastrointestinal tract

HHV-6 infection in 247-8 Gauss-Newton optimization algorithm 327-30 genes, of HHV-6 code 266 genome 8, 9, 11, 24-6

classification and biology 23-4 composition and molecular biology 29-38 conserved and specific genes 38-9 HHV-6 strains 39-43 rearrangements and relationships 29 strain groups 24

structure and repetitive sequence 26-9, 27f, 40f variation, inspection 39-43 genome composition strain U1102 genes, features 31t-36t genome structure, HHV-6 with herpesvirus and betaherpesvirus conserved genes 27f repetitive sequence 26-9 with strain conserved and variant genes 40f Gianotii-Crosti syndrome 245 glial fibrillary acidic protein (GFAP) 215 glycoprotein B (gB) 49f, 52 glycoprotein H (gH) 53 glycoprotein L (gL) 53 glycoprotein O (gO) 54 glycoprotein Q (gQ) 53-4 Gougerot-Sjogren's syndrome (SS) 190

lymphomas in 194 graft-versus-host disease (GVHD) 163, 169, 206, 286

in HSCT recipients 165, 166-7

HCMV see human cytomegalovirus heart diseases 236-9 helicase-primase 298

hematopoietic stem cell transplant (HSCT) recipients 247

skin rash and HHV-6 reactivation 165-7 hemophagocytic syndrome (HSP) 141, 152, 153, 245-6

hepatic injury see liver disease hepatitis 151

HHV-6 associated, pathogenesis of 246-7 HHV-6 infection 243-5 hepatotropic viruses 285 HepG2 cells 246 herald patch 168 Herpesviridae 7, 11, 29, 307 HHV conserved genes 27f, 38-9 HHV-6 variants 9-10, 307 detection 191 exanthema subitum 307 see also strain variants HHV-6A 8-10

see also isolates CO1 HHV-6B 8-10

HHV-7, cellular tropism 24-6

for T lymphocyte 25 HHV-8 8, 12-13, 13t transactivation 197 HIV-1 and HHV-6 infection 263 correlations 270-1

direct immunological damage, mechanism of 268-9

experimental coinfection models 271-4 in vitro interactions 264-8 in vivo studies 269-71 Hodgkin's disease (HD) 194, 201 with EBV 192

lymph nodes, HHV-6 characteristics 190-1 in RS cells 192 scleronodular HD 191-2 homeostasis 325-6 host cell chromosomal DNA HHV-6 integration 197-8 HSB-2 cells 49f, 339 HSV-1 8, 9, 12, 13f capsids 15, 18f human B-lymphotropic (HBLV) virus 6, 7, 62

human cytomegalovirus (HCMV) 8, 9, 11, 47,

100, 133 human fetal astrocytes 64 human genes, transactivation 196-7 human immunodeficiency virus (HIV) 201,

207-9, 308 human lymphoid tissue ex vivo 62, 70-1, 271-2

human measles virus 203

human umbilical vein endothelium (HUVEC)

viral antigens 234 hyperimmune response 252 hyperplastic lymph nodes 139

immediate-early (IE) genes 38, 48 immediate-early (IE) proteins 47-9 IgG 229, 255, 269 IgM 255 antibody 91, 95, 96, 225 responses 99, 216, 226 interleukin-8 (IL-8) 246 ImmuKnow 206-7 immune dysfunction 252-3 immune modulation 67-70 CD3 coengagement 70 clinical and experimental evidence 67 emerging hypothesis 68 PBMC 69 viral genomes 69 virus 68

immunocompromised individuals AIDS-related LD 194-5 post-transplant LD 194 immunodeficiency disorders 202

immunofluorescence assay (IFA) staining 49f, 92-3, 186

of HHV-6-infected human cordblood mononuclear cells 6f immunoglobulin 337-8 immunological damage, mechanisms 268-9 immunological tools 206-9 immunomodulatory therapy, in CFS patients 259

immunosuppressed populations, comparison 207-9

immunosuppression 205-6, 210, 226 in vitro human endothelial cells 64 in vitro interactions, HIV-1 264-8 CD4 + T cells, productive coinfection 264f, 265-6

de novo CD4 expression 267-8 inflammatory cytokines, induction 268 LTR transactivation by HHV-6 266 reciprocal effects, on HHV-6 replication 266-7 virion-virion interactions 267 in vivo cellular effects 135 incubation period 125-6, 151 indirect immunofluorescence assay 49f induced inflammatory CNS demyelination in vivo persistence and replication 313 lytic effect, on CNS glial cells 316 serum antibody reactivity, to viral antigens

Was this article helpful?

0 0

Post a comment